Investors

2017 News

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
Feb 08, 2017CTI BioPharma to Present at the BIO CEO & Investor Conference
SEATTLE, Feb. 8, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that management will present at the the BIO CEO & Investor Conference on Tuesday, February 14, 2017, at 8:00 a.m. ET/2:00 p.m. CET in New York. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma CTI BioPharma Corp. is a biopharmaceutical company focused on the ac... 
Printer Friendly Version
Jan 24, 2017CTI Biopharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors
SEATTLE, Jan. 24, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Michael A. Metzger has been appointed a Director of CTI BioPharma. Mr. Metzger brings extensive experience leading and growing companies in the biopharmaceutical industry over the last 20 years. "We are pleased to welcome Michael to the Board of CTI BioPharma," said Richard Love, Interim President and CEO of CTI BioPharma. "Michael is an accomplished leader and builder of bio... 
Printer Friendly Version
Jan 09, 2017CTI BioPharma Announces Progress Of Lead Programs And Strategic Objectives For 2017
SEATTLE, Jan. 9, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced positive progress on its lead programs in addition to key business priorities for 2017. "Throughout 2016 we maintained our commitment to bringing new therapies to patients with unmet medical needs, and were successful in working with the FDA to remove the full clinical hold on pacritinib and get it back on the development track for the benefit of myelofibrosis patients," said Richa... 
Printer Friendly Version
Jan 05, 2017CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib
SEATTLE, Jan. 5, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the full clinical hold (February 2016) implemented by the U.S. Food and Drug Administration (FDA) on all clinical trials conducted under the Investigational New Drug (IND) application for pacritinib has now been removed. The Company's complete response submission included, among other items, final Clinical Study Reports for both PERSIST-1 and 2 trials and a dose-exploration clini... 
Printer Friendly Version